newsfilter
← Latest News
Earnings Call Transcripts·

STIFEL 2026 HEALTHCARE CONFERENCE - Zymeworks Inc.

ZYME

  • Financial Performance:

    • Zymora (Zeny) has a peak sales potential of $3-$5 billion (Jazz guidance), translating to $500M-$900M in annual royalty income for Zymora.
    • Generated $250 million in debt financing from Royalty Pharma against future Zeny royalties.
    • Repurchased over 14 million shares (~20% of company) over the last two years; $150 million+ in buybacks executed this year alone.
    • Q3 earnings highlighted improved financial components; core R&D budget reduced by 20% from previous year but remains substantial.
    • TheraVance acquisition funded partly by royalty debt proceeds; expected mid-teens IRR driven by modest growth and utilization of R&D assets/tax attributes.
    • Upcoming $55 million upfront payment from Roche deal expected in December.

  • Guidance and Future Outlook:

    • Management targets "sustainable profitability" through a diversified model balancing R&D, capital returns, and M&A.
    • 2027-2028 focus on replicating 2024-2026 success, turning R&D innovation into shareholder value without balance sheet overextension.
    • No predetermined capital allocation formula; excess cash flow will be deployed opportunistically across R&D, buybacks, or M&A.
    • Long-term goal to maintain "unencumbered" R&D on balance sheet while leveraging partnerships or spin-outs for capital-intensive programs.

  • Business Segments and Product Lines:

    • Zeny (Xanidatamab): HER2-targeted ADC; commercialized in US via Jazz partner; approved for GEAs with median OS benefit of 8 months.
    • ZW191: Full-receptor alpha targeting ADC; >70% ORR in label indication (vs. 40% for competitor mervutuximab); seeking strategic partner due to competitive gynecological tumor landscape.
    • ZW251: GPC3-targeted ADC for HCC; early clinical development; less competitive environment than ZW191; potential for frontline combination with immunotherapy.
    • ZW209: DLL3-targeted ADC partnered with Roche; launched in clinic; utilizes COSTIM platform.
    • TheraVance: Acquired commercial product (Povary) co-promoted with Beatrice; adds commercial revenue stream.
    • Pan-RAS ADCs: Four development candidates; potential for future spin-off with financial investors to fund development while retaining equity/royalty upside.
    • Pipeline Innovation: Tri-specific PD-1/VEGF/IL-7 and first-in-class penta-specific antibody (5-arm) disclosed; logic-gated for AML.

  • Market and Competitive Landscape:

    • Gynecological tumor ADC market is "flooded" with unselected approaches, necessitating ZW191 partnership for resource efficiency.
    • Zymora emphasizes unique differentiation (e.g., Xanidatamab, ZW209, ZW191) to avoid binary risks of commoditized assets.
    • Roche partnership validated the potential of controlled single-biologic T-cell engager combinations (DLL3) over separate bispecifics.
    • Management views M&A as an opportunity to find "mispriced" assets others cannot value, citing TheraVance as a unique win.

  • Risks and Challenges:

    • Capital constraints: Funding the entire diverse R&D portfolio on the balance sheet alone is not viable; reliance on partnerships/spin-outs introduces execution complexity.
    • Competitive pressure in gynecological tumors requires external resources to validate and commercialize ZW191.
    • Dependency on partner success (Jazz, Roche, Beatrice) for royalty streams and commercialization.
    • Binary clinical risk inherent in early-stage assets (e.g., Pan-RAS ADCs) requires careful capital allocation to avoid shareholder value destruction.

  • Management Commentary and Tone:

    • Tone is confident, optimistic, and strategically focused on a "diversified business model" that decouples R&D innovation from balance sheet risk.
    • CEO Ken Galbraith emphasizes the company's unique engineering capabilities (e.g., penta-specific antibodies, COSTIM platform) as a moat.
    • Management rejects "traditional biotech dogma" of forward-integration sales forces, preferring partner models for risk-adjusted returns.
    • Emphasizes "share of success" rather than 100% ownership, prioritizing long-term total shareholder return over asset control.

  • Analyst Questions and Answers:

    • Capital Allocation: Confirmed a three-pillar approach (Core R&D, Shareholder Returns, Opportunistic M&A) with no fixed ratio; decisions are stage-agnostic and data-driven.
    • ZW191 Partnership Strategy: Acknowledged competitive pressures; seeking a partner with belief in the molecule rather than rushing to market alone; similar to the Zeny/Jazz dynamic.
    • Spin-out Feasibility: Confirmed ability to spin off assets (e.g., Pan-RAS ADCs) at various stages to access financial capital while retaining equity/royalty stakes.
    • Roche Deal Timing: The DLL3 deal occurred shortly before tarlatamab data, signaling Roche's belief in the platform and providing validation for combination strategies.
    • Valuation Maturity: Early-stage asset valuations are healthy; management will not pre-determine development stage for partnership, waiting for specific strategic fit (e.g., Roche's immunotherapy access for ZW209).

  • Other Key Points:

    • Zymora is the only company developing a penta-specific antibody (5-arm) for AML.
    • The company is actively exploring a "spin-out" model with financial investors (not just pharma) to keep the core portfolio unencumbered.
    • Management highlighted the "logic-gated" nature of their penta-specific antibody as a unique engineering achievement.
    • The TheraVance deal was executed at a "fair price" without the "bidding war" inflation common in the sector.
    • Zymora views its success as a repeatable process: identify unique innovation, partner or spin-out for capital, and capture share of success.